Table 5.
Effect of PPAR-γ agonists on the histological grading of ankle synovium in arthritic rats.
| Parameter | Normal controls | AIA controls | AIA + ROSI 10 | AIA + PIO 30 |
| Synoviocyte hyperplasia | 0 ± 0 | 3.93 ± 0.12* | 2.00 ± 0.42# | 0.80 ± 0.19# |
| Focal aggregates of lymphocytes | 0.08 ± 0.14 | 3.50 ± 0.24* | 1.60 ± 0.23# | 1.20 ± 0.19# |
| Fibrosis | 0.37 ± 0.26 | 3.73 ± 0.20* | 2.60 ± 0.31# | 1.00 ± 0.30# |
| Proliferating blood vessels (original magnification × 40) | 0.37 ± 0.26 | 1.50 ± 0.24* | 0.80 ± 0.35 | 1.07 ± 0.12 |
| Perivascular infiltrates of lymphocytes | 0.62 ± 0.26 | 1.60 ± 0.31* | 0.80 ± 0.35 | 1.10 ± 0.25 |
| Diffuse infiltrates of lymphocytes | 0 ± 0 | 3.13 ± 0.16* | 2.10 ± 0.25# | 0.70 ± 0.22# |
PPAR, peroxisome proliferator-activated receptor; ROSI 10, rosiglitazone 10 mg/kg/day; PIO 30, pioglitazone 30 mg/kg/day; AIA, adjuvant-induced arthritis. Data are expressed as means ± SEM (n = 5 representative animals per group).
*, P < 0.05 compared with normal controls; #, P < 0.05 compared with AIA controls (Mann–Whitney U test).